NVS - Novartis AG Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

NVS

NOVARTIS AG

NYSE

$153.81

▼ DOWN 0.54% (-0.84)

KEY STATISTICS

Market Cap$292.35 B

52w High$170.46

52w Low$121.57

Dividend Yield3.04%

FrequencyAnnual

P/E17.70

Volume1.17M

Shares Out.1.90B

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Vasant Narasimhan

ABOUT

SECTOR

Healthcare

WENT PUBLIC

November 7, 1996

METHOD OF GOING PUBLIC

N/A

FULL TIME EMPLOYEES

75,267

PRICE TARGET

Target High$170.00

Target Low$170.00

Target Median$170.00

Target Consensus$170.00

UPCOMING EARNINGS

DateOct 27, 2026

DayTuesday

Rev. Est.$14.59B

OCT

TUE

SPLIT RECORD

DATE	TYPE	RATIO
2019-04-09	Forward	279:250
2000-05-11	Forward	2:1

PRICE

$153.81 ▼ DOWN 0.54% (−$0.84)

OVERLAYS

About Novartis AG

https://www.novartis.com ↗

Novartis AG, headquartered in Basel, Switzerland, develops and markets healthcare products worldwide through its Innovative Medicines and Sandoz segments, offering prescription medicines, biosimilars, generics, and biotech products.

INDUSTRY

Drug Manufacturers - General

A PRODUCT NOVARTIS AG IS KNOWN FOR

Rhapsido® (remibrutinib)

Rhapsido® is the first approved oral BTK inhibitor for adult chronic spontaneous urticaria patients unresponsive to antihistamines, representing an innovative, growth-driving addition to Novartis's immunology portfolio.

COMPETITORS

COMPETITOR

Revenue by Products

PRODUCT	Q2-2020	Q2-2021	Q2-2022	Q2-2023
Top 20 products	$7.1B	$8.23B ▲	$8.26B ▲	$8.79B ▲
Rest of portfolio	$2.08B	$2.33B ▲	$2.2B ▼	$2.45B ▲
Total antiinfectives net sales	—	$257M	$276M ▲	—
Anti Infectives sold under Sandoz name	$134M	$161M ▲	$183M ▲	—

Revenue by Geography

REGION	FY2019	FY2020	FY2021	FY2022
Other Countries	—	$19.04B	$20.81B ▲	$20.05B ▼
UNITED STATES	$16.28B	$16.48B ▲	$16.82B ▲	$17.65B ▲
GERMANY	$4.12B	$4.52B ▲	$4.87B ▲	$4.28B ▼
CHINA	—	$2.57B	$3.05B ▲	$3.13B ▲
FRANCE	$2.44B	$2.44B	$2.52B ▲	$2.26B ▼
JAPAN	$2.66B	$2.8B ▲	$2.68B ▼	$2.21B ▼
Country of domicile	—	$800M	$873M ▲	$970M ▲